Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)
On February 19, Travere Therapeutics Inc. (NASDAQ:TVTX) released the fourth quarter earnings report. The company registered U.S.
Travere Therapeutics Inc. (TVTX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 3,512 | $104,342 | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.85 | 5,000 | $89,250.00 | 245,556 | 2017-06-14 | Filing | |
| $15.31 | 5,000 | $76,564.50 | 52,000 | 2016-03-04 | Filing | |
| $8.60 | 15,000 | $129,049.50 | 35,000 | 2014-11-25 | Filing | |
| $8.38 | 6,100 | $51,118.00 | 129,165 | 2014-11-21 | Filing | |
| $8.50 | 8,700 | $73,950.00 | 371,756 | 2014-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $41.07 | 8,000 | $328,560.00 | 57,500 | 2026-04-14 | Filing | |
| $42.12 | 6,750 | $284,310.00 | 37,500 | 2026-04-14 | Filing | |
| $41.07 | 26,000 | $1,067,820.00 | 44,250 | 2026-04-14 | Filing | |
| $41.07 | 21,977 | $902,595.39 | 42,353 | 2026-04-14 | Filing | |
| $41.93 | 7,215 | $302,516.29 | 138,608 | 2026-04-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 28,161 | $836,663 | 0.02% | |
| 2. | 19,162 | $569,303 | 0.02% | |
| 3. | 2,298 | $68,274 | 0% | |
| 4. | 2,009 | $59,687 | 0% | |
| 5. | 1,553 | $46,140 | 0% |
News See All
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory
We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled.
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026.
10 Best Stocks for Beginners with Little Money in 2026
On February 19, Joseph Stiglitz, the Nobel Prize-winning economist and ‘The Road to Freedom’ author, joined CNBC's 'Squawk Box' to discuss the state of the economy and argued that conditions are poor...
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2025 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2025 Earnings Call Transcript February 19, 2026Travere Therapeutics, Inc. reports earnings inline with expectations.
Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market
TheFly reported on February 6 that Piper Sandler raised its price target on TVTX to $38 from $35 and maintained a Neutral rating on the shares.
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best mid-cap growth stocks to buy right now.
14 Best Mid-Cap Growth Stocks to Buy Right Now
On January 8, Nancy Prial, Co-CEO & Senior Portfolio Manager at Essex Investment Management, appeared on CNBC and suggested she sees significant upside in 2026 for undiscovered small- and midcap firms...
Hedge Fund Resource Center